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INTRODUCTION: Patients with complex conditions
account for a disproportionate share of health care
spending. Although evidence indicates that care for
these patients could be provided more efficiently, the
financial impact of mechanisms to improve the care
they receive is unclear.
DESIGN/METHODS: Numerous mechanisms—empha-
sizing patient self-management, care coordination, and
evidence-based guidelines—aim to improve the quality
of care and outcomes for patients with complex condi-
tions. Assessing the overall “business case” for these
mechanisms requires carefully estimating all relevant
costs and financial benefits, then comparing them in
present value terms. Mechanisms that are not cost-
saving may still be implemented if they are cost-
effective. We reviewed articles in peer-reviewed journals,
as well as reports available on publicly accessible
websites, which contained data about the business
case for mechanisms to improve care for patients with
complex conditions.
MAIN RESULTS: Published studies do not provide clear
evidence that current mechanisms are cost saving. This
literature also has several major methodological short-
comings with respect to providing an understanding of
the business case for these mechanisms.
CONCLUSIONS: Further research using standardized
methodologies is needed to understand the business
case for mechanisms to improve care for patients with
complex conditions. Implications for VA business case
analyses include the necessity of establishing appropri-
ate time horizons, scope of services, and target popula-
tions, as well as considering the impact of existing VA
systems.
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INTRODUCTION
Patients with complex chronic conditions account for a dispro-
portionately high share of spending in any health care system.
1
For example, the 23% of Medicare beneficiaries with 5 or more
chronicconditionsincur68%oftheprogram’ssp en di n g.
2Among
veterans age 65 and older, the 10 most expensive chronic
conditions account for 66% of total VA costs for those persons.
3
However, analyses at the national level also indicate that
spending for patients with severe chronic illness could be
greatly reduced without compromising the quality of care.
4 For
defined populations of patients, advocates of tools such as the
Chronic Care Model or disease management assert that such
mechanisms can both reduce costs and improve quality.
Policy makers and managers within health care systems
want to know which specific interventions or tools can control
costs for care of patients with complex conditions while
maintaining or improving the quality of care and patient
outcomes. Managers describe interventions or tools (hence-
forth “mechanisms”) that meet these criteria as having a
favorable “business case.”
This paper reviews published findings about the business
case for mechanisms to improve care for patients with complex
conditions. It was originally prepared for the Department of
Veterans Affairs (VA) 2006 State of the Art (SOTA) conference
“Managing Complexity in Chronic Care.” In the Methods
section below, we (1) briefly describe the types of mechanisms
used to improve care for patients with complex conditions; (2)
outline a framework for analyzing the business case for these
mechanisms; and (3) summarize the literature review process
we undertook. Subsequent sections summarize the available
evidence about the financial impact of implementing these
mechanisms and conclude by highlighting priorities for future
research and some implications for the VA health care system.
METHODS
Mechanisms to Improve Care for Patients
with Complex Conditions
Patients with complex conditions have diverse and multiple
diagnoses, including: diabetes and other chronic conditions;
cancer; HIV disease; neurological disorders; autoimmune
diseases; physical disabilities; and severe mental illness. These
patients are often seen by multiple clinicians—specialists as
well as primary care physicians—in multiple care settings.
They have elevated risks of receiving poor quality care as well
as incurring avoidable costs.
1 These risks include: preventable
hospitalizations; avoidable emergency department use; dupli-
cate testing; polypharmacy; poor communication of essential
clinical information across different physicians and care
settings; potentially conflicting treatment strategies; and seri-
ous negative outcomes from poor compliance with treatment
recommendations (see Fig. 1).
396Awide variety of mechanisms are employed to mitigate these
risks and thereby improve care for patients with complex
conditions (also see Fig. 1). Some of these mechanisms, such
as the Chronic Care Model (CCM) and organized care manage-
ment processes, are primarily implemented by physician
organizations, whereas others, such as disease management,
are most often implemented by health plans; ideally, comple-
mentary mechanisms should be coordinated among a patient’s
physicians and health plan.
5–7 Table 1 describes these
mechanisms in more detail.
Medicare is conducting several demonstration programs,
each implementing different sets of mechanisms to improve
care for fee-for-service beneficiaries with complex conditions.
8
In the Physician Group Practice Demonstration, large multi-
specialty group practices will share in Medicare savings if they
successfully improve cancer screening and care for 4 chronic
conditions. Medicare Health Support is a large-scale disease
management program for beneficiaries with CHF and/or
complex diabetes. Contracts have been awarded to disease
management vendors and health plans that have promised to
achieve quality improvement and beneficiary satisfaction
targets, as well as net financial savings of at least 5%. Two
other demonstrations are targeting high cost or severely
chronically ill beneficiaries.
Many state Medicaid programs are implementing mecha-
nisms to improve care for patients with chronic disease or
other complex conditions. There is wide variation across states
in the groups of patients targeted, the mechanisms chosen,
and the implementation strategies used.
9–11
Business Case Analysis
An analysis of the business case for implementing a set of
mechanisms explicitly compares the estimated benefits of
x
x
x
x
x
x
Figure 1. Impact of Improved Care for Patients with Complex Conditions
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12 The
business case is positive if financial benefits exceed costs while
maintaining or improving quality. The business case would
also be positive if implementing a set of mechanisms improved
quality but did not produce a net cost increase.
Estimates of benefits and costs must meet specific crite-
ria.
13 First, all costs related to the implementation must be
included. Second, future costs and benefits should be dis-
counted to the present to account for the time value of money.
If the present value of estimated benefits exceeds the present
value of estimated costs, the financial return on investment
(ROI) is positive.
Estimating Costs. For mechanisms to improve care of patients
with complex conditions, estimated costs should include:
Startup costs, for example, new information systems, data
collection and analyses to identify target patients, or initial
training for physicians and staff;
Direct costs, for example, new staff, additional physician time,
or additional nursing time to communicate with patients;
Indirect costs
14 attributable to the mechanism, for example,
higher utilization of screening tests or chronic disease medica-
tions, or senior management participation in implementation.
Estimating Benefits. Estimating financial and clinical benefits
requires projecting how the mechanism(s) will change the
frequency of future events. Estimating the impact of efficiency
improvements, such as eliminating duplicate testing, is
relatively straightforward. Estimating cost savings from
reductions in more rare events such as preventable
hospitalizations requires more sophisticated analyses.
15
Estimating the benefits of preventing future complications of
chronic disease is most challenging. The further in the future
those complications would occur, the greater the uncertainty
of the underlying statistical projections.
Two important methodological issues must be addressed in
measuring benefits.
16 First, cost reductions must be adjusted
for expected regression to the mean. Patients are often
identified to participate in a mechanism based on a history of
high costs or a sentinel event, such as a hospitalization.
However, some patients in the highest-cost group in a given
year will inherently have lower costs in subsequent years.
17
The second issue is selection bias. Patients who enroll in
pilot or demonstration programs may be those most motivated
to change their behavior, and therefore would have had
reduced future costs even without the mechanism(s). Extrap-
olating benefits from these patients’ experience may overesti-
mate the benefit of the mechanism(s) for a larger population.
The business case for a mechanism is less favorable when
the organization that bears its costs does not realize all the
resulting benefits. For example, physician organizations that
implement mechanisms to decrease avoidable hospitalizations
may see the benefits accrue to health plans. A commercial
health plan would not count some savings from preventing
future complications of chronic disease, because they accrue
after the patient is likely to have left the plan.
Cost-Effectiveness Analysis. The standard business case
analysis method does not provide managers with adequate
guidance about whether to implement mechanisms that
improve quality but also increase costs, and therefore do not
have a positive financial ROI. A health plan or integrated
health care system may still decide to implement such
mechanisms if they sufficiently improve health outcomes.
Cost-effectiveness analysis (CEA) can help guide these
decisions.
18–20 CEA quantifies benefits in quality-adjusted life
years (QALYs), not dollars. QALYs incorporate both years of life
gained (delayed mortality) and future quality of life (reduced
morbidity). CEA compares the cost per QALY gained from
different mechanisms. Those with the lowest cost per QALYare
recommended for implementation first, if incremental funds
are available to the organization. However, if the overall budget
for a population is fixed (as in the VA), implementing new, cost-
effective mechanisms means reducing funding for existing, less
cost-effective activities, which can be quite difficult politically
and organizationally.
12, 21
Literature Review Process
We performed a literature review to identify and synthesize
published documents—articles in peer-reviewed journals as
well as reports available on publicly accessible websites—that
contained data about the business case for mechanisms to
improve care for patients with complex conditions. To identify
these documents, we initially conducted a series of keyword
searches in PubMed, then subsequently searched (using
PubMed or the Google search engine) for additional documents
referenced in the articles and reports retrieved. Searches were
constrained to documents published in English after 1995.
Search terms included the mechanisms described above
and in Table 1, as well as terms focused on the business case
(that is, costs, financial benefits, cost effectiveness, or econom-
ic evaluation) for those mechanisms. We further searched for
articles on variation, utilization, and cost for patients in the VA
health care system. We reviewed citations for over 700 articles
or reports retrieved from these searches; over 200 abstracts or
Table 1. Mechanisms to Improve Care for Patients with Complex
Conditions
Mechanisms
The Chronic Care Model (CCM) is a 6-element quality improvement
model for primary care of patients with chronic disease.
54, 55
Physician organizations, whether or not they explicitly follow the CCM,
can employ one or more care management processes (CMPs).
6, 56–58
These include:
￿Self-management support
￿Group visits
59
￿Registries of patients with each chronic disease
60, 61
￿Evidence-based clinical practice guidelines
￿Reminders (paper or electronic)
￿Performance feedback to physicians
￿Electronic medical records
￿Case managers
Disease management programs, usually offered by health plans,
typicallyprovide patients with information about theirchronic disease(s),
promote positive health behaviors and treatment compliance, and
may provide data to the patients’ physicians
62–64
Health plans and physician organizations employ case management to
coordinate the care provided to their sickest or most costly patients.
65
Telemedicine systems use information technology and
telecommunications to enable clinicians distant from patients to make
diagnoses, provide treatment recommendations, and conduct home
monitoring.
66, 67
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volume of documents describing interventions for specific
diseases was so large, we selected for deeper analysis: reviews
that synthesized financial or economic findings from large
numbers of studies; rigorous case study analyses; and reports
on specific Medicare or Medicaid programs or VA studies. We
synthesized the findings from these documents with respect to
the aspects of business case analysis described above.
RESULTS
The published literature on the business case for mechanisms
to improve care for patients with complex conditions is limited.
The following meta-analyses, systematic reviews, or rigorous
literature reviews summarize the benefits and costs of a variety
of mechanisms:
Bodenheimer and colleagues’
22 review of 39 studies of the
implementation of 1 or more CCM components for patients
with CHF, asthma, or diabetes found mixed evidence of
reduced cost or utilization. They noted that improvements in
care for these diseases has the potential to reduce expendi-
tures, if reimbursement systems are properly structured.
Richardson and colleagues
23 reviewed 39 studies of the cost
impact or cost effectiveness of interventions to support self-
care. Although most studies asserted positive economic
results, the reviewers found most of the study designs to be
seriously flawed.
The Congressional Budget Office
24 examined 48 peer-reviewed
studies of disease management programs for CHF, CAD, and
diabetes. They did not find evidence that these programs
reduced costs. Most studies, in fact, did not present cost data.
(This review has been criticized for not including some peer-
reviewed studies, particularly those published in the journal
Disease Management
25).
Weingarten and colleagues
26 performed a meta-analysis of 102
studies of the effectiveness of 118 disease management
programs for 12 chronic diseases. Financial data were reported
for only 6 of the programs. A subsequent systematic review of
the same articles by Ofman and colleagues
27 found that only
69 of 351 reported measures related to cost or utilization, and
of these only 9 were statistically significant.
Goetzel and colleagues
28 reviewed 44 published and high-
quality unpublished studies of the economic impact of disease
management for 5 conditions. Programs for CHF or patients
with multiple conditions appeared to have a positive ROI. ROI
results were inconclusive for diabetes and asthma programs,
whereas programs for depression were modestly cost increasing.
Krause
29 performed a meta-analysis of the “direct economic
outcomes” of 67 disease management programs for asthma,
diabetes, and CAD. One cost or utilization measure was
included per study. A statistically significant effect size of
0.31 was found; patient disease severity was a statistically
significant moderating variable.
Maciosek and colleagues
30 reviewed the available literature on
the cost effectiveness of 25 clinical preventive services recom-
mended by the US Preventive Services Task Force or the
Advisory Committee on Immunization Practices. Only 5 of the
services were cost-saving; an additional 10 services had a
cost/QALY below $35,000.
Hailey and colleagues’
31 systematic review of 25 telemedicine
studies that included economic analyses found indications
that some telemedicine applications could reduce costs, but
did not specify which of these applications apply to patients
with complex conditions. Whitten and colleagues
32 systemat-
ically reviewed 24 studies and did not find evidence that
telemedicine was cost-effective, owing to methodological short-
comings of the studies’ economic analyses.
Ouwens and colleagues
33 performed a review of systematic
reviews of “integrated care programmes” (comprising a variety
of mechanisms) for patients with chronic disease. Seven of the
13 reviews addressed costs, of which 4 showed reductions
(none statistically significant) and 3 showed unclear findings.
Seven reviews addressed hospitalization, of which 6 showed
reductions (3 of them statistically significant) and 1 showed
unclear findings.
A few rigorous case studies provide some additional insights.
Leatherman and colleagues
34 reported on 4 carefully designed
case studies of chronic disease management or wellness
programs. All were estimated to produce a positive long-term
financial impact. However, because initial costs were high
while benefits accrued in the future, the business cases for the
programs were not positive.
The Permanente Medical Group of Northern California (TPMG)
instituted a disease management program for members with
CAD, CHF, diabetes, or asthma. The program produced quality
improvements but not cost savings.
35 However, TPMG’s pre-
existing organized processes of care may have limited the
incremental cost savings realizable from the disease manage-
ment program.
The Center for Studying Health System Change, reporting on
its ongoing study of 12 health care markets nationwide,
characterized disease management and case management as
still being a financial “leap of faith” for employers and health
plans.
36
The evidence regarding the benefits and costs of mecha-
nisms to improve care for patients with complex conditions in
Medicare and Medicaid is unclear. The Medicare demonstra-
tions described above have not yet reported evaluation results.
The Medicare Coordinated Care Demonstration, comprising 15
diverse programs (primarily offering disease management
services), reported no clear quality benefits and no reduction
in Part A and Part B services during its first 2 years.
37 The
diversity of states’ Medicaid care coordination programs, as
well as their relatively recent implementation, makes it difficult
to comparatively evaluate their financial impact. For example,
many Medicaid disease management programs report cost
savings, but questions have also been raised about the validity
of those estimates.
38, 39
The limited literature describing the benefits and costs of VA
mechanisms to improve care for veterans with complex condi-
tions provides both cautionary and hopeful findings. A rigor-
ously evaluated primary care case management mechanism
for severely ill veterans with diabetes, COPD, or CHF did not
reduce rehospitalization as expected.
40 A multisite randomized
trial of team-managed home-based primary care for severely ill
veterans improved patient and caregiver quality of life, but also
increased costs.
41 A randomized multisite trial of a collabora-
tive care model for bipolar disorder produced some improved
outcomes over 3 years, and was cost neutral.
68
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Patients with complex conditions, especially those with multi-
ple or severe chronic conditions, incur a large proportion of
spending in any health care system. Avariety of mechanisms—
emphasizing patient self-management, care coordination, and
evidence-based guidelines—may help to control costs for those
patients while improving or maintaining quality. Assessing the
business case for these mechanisms requires carefully esti-
mating all costs and financial benefits, then comparing them
in present value terms. Mechanisms that are not cost-saving
may still be implemented if they are cost-effective.
The published literature does not provide clear evidence
that mechanisms to improve care for patients with complex
conditions have a favorable business case, that is, are cost-
saving or can improve quality without increasing costs. One
contributor to this lack of evidence is that, whereas most
published studies of these mechanisms measure processes of
care, outcomes, and/or patient satisfaction, only a minority
measure costs and financial benefits.
This literature has several specific methodological short-
comings with respect to providing an understanding of the
business case for mechanisms to improve care for patients
with complex conditions:
1. Mechanisms evaluated. Most published studies report
evaluations of individual programs, each comprising a
unique set of component mechanisms. Because there is
no standardized taxonomy of mechanisms, it is difficult to
compare the impact of defined sets of mechanisms across
studies or to assess the contributions of individual
mechanisms. The problem is compounded when compar-
ing published reviews, each of which has its own strategies
for selecting which studies to include or exclude.
2. Costestimates.Asmentionedabove,mostpublishedstudies
do not measure costs. Of those that do, only very few
measure startup, direct, and indirect costs with adequate
scope and precision to support business case analyses.
3. Benefit estimates. Benefit measures in published studies
are usually nonfinancial (e.g., reduced hospitalizations or
emergency department use), and are seldom adequately
comprehensive in scope to capture all potential benefits.
4. Benefit timeframes. Studies commonly measure short-
term benefits (2 years or less), although other benefits
take years to materialize. This is problematic because
short-term utilization reductions may not translate into
analogous lifetime cost savings.
5. ROI analysis. The shortcomings in most published stud-
ies’ cost and benefit measurements make it virtually
impossible to calculate or compare ROIs based on ade-
quate present value analyses.
6. Cost-effectiveness analysis. Formal cost effectiveness
analyses are seldom mentioned in published studies.
And only 3 of the 11 reviews summarized above explicitly
address the cost effectiveness of the studies they review.
Future Research
Further research is needed to understand the business case
for mechanisms to improve case for patients with complex
conditions. However, conducting such research is challenging:
it involves evaluating multifaceted mechanisms at multiple
sites; must account for variations in organizational structure
and culture; should include randomized designs and control
groups; must incorporate standardized, comprehensive mea-
sures of costs and financial and clinical outcomes; and may
produce findings difficult to generalize across diverse underly-
ing diseases. There is currently no standard set of cost or
financial benefit measures or methodology for applying
them.
42 T h e r ei sa l s on os t a n d a r ds o u r c ef o rt h eQ A L Y
estimates needed for cost effectiveness analyses.
Standardized frameworks for evaluating the clinical and
financial aspects of disease management programs may offer
guidance for research about the business case for other
mechanisms. These frameworks have been proposed from the
perspective of health services research
20, 43, 44 and by disease
management practitioners and industry associations.
45–47
However, more data are needed about the effectiveness, costs,
and benefits of programs to improve care for patients with
multiple chronic conditions.
1, 48
Implications for the VA Health Care System
The VA is well positioned to measure the financial impact of
mechanisms to improve care for patients with complex condi-
tions and to reap the potential benefits from them. VA
managers and researchers can draw several implications from
the literature about these mechanisms in other settings.
First, VA business case analyses should use a sufficiently long
time horizon in estimating costs and benefits. Although
patients with complex conditions may not stay in a commercial
health plan long enough for mechanisms to pay off, veterans
retain VA eligibility for life. Because Medicare and Medicaid
beneficiaries also have lifetime or long-term eligibility, the
anticipated results from evaluations of mechanisms for
patients with complex conditions in those programs may be
especially informative for the VA.
Second, VA business case analyses must consider the cost of
VA services that are not covered by commercial health plans or
Medicare, particularly long-term care and mental health care.
Estimated reductions in the utilization of these services may
have a significant financial impact.
Third, the literature offers preliminary indications that target-
ing mechanisms to the highest-risk veterans, such as those
with multiple chronic conditions, may produce greater finan-
cial benefits.
1, 49, 50
Fourth, the VA should determine whether disease management
or case management better meets the needs of veterans with
complex conditions. Is the financial benefit greater from
providing prevention and health promotion services to all
veterans with chronic disease (many of whom are not complex)
or from focusing intensively on the smaller number of high-
utilizing veterans (where disease has already progressed)? This
question is especially important for the VA (and Medicare),
because the prevalence of multiple chronic conditions is much
higher than in the populations served by commercial disease
management programs that usually focus on a single dis-
ease.
51 Even in the commercial market, some health plans are
emphasizing case management, believing it targets their
resources more effectively.
36, 50
400 Luck et al.: Business Case for Complex Conditions JGIMFifth, the VA already has in place several of the mechanisms
described above, such as the computerized patient record
system (CPRS) to facilitate communication among multiple
physicians, multidisciplinary care teams, the My HealtheVet
online patient information system, performance feedback to
facilities, practice guidelines, and the Quality Enhancement
Research Initiative (QUERI). These capabilities may reduce the
potential benefits of some other mechanisms. Conversely, they
may help the VA to implement more focused or sophisticated
mechanisms, such as telemedicine.
52, 53
Sixth, focused research could identify opportunities to improve
care for veterans with complex conditions, and document the
baseline against which mechanisms can be evaluated. Poten-
tial topics include characteristics of high-cost veterans, varia-
tions in utilization across VA facilities, and preventable VA
hospitalizations.
CONCLUSIONS
Patients with complex conditions account for a large propor-
tion of health care spending, and are often at risk for poor
quality of care and outcomes. Although a variety of mecha-
nisms aim to improve care for these patients, their long-term
financial impact is still poorly understood. More research is
needed to better understand their financial impact and cost
effectiveness. The VA, because of its integrated financing and
care provision, comprehensive information systems, and per-
formance measurement capabilities, could play a leading role
in evaluating the business case for such mechanisms and in
implementing those that are shown to be cost-saving or cost-
effective.
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